Related Experiment Video
Updated: May 3, 2026

Hemodynamic Precision in the Neonatal Intensive Care Unit using Targeted Neonatal Echocardiography
Published on: January 27, 2023
EBNEO Commentary: Expectant Management Versus Medication for Patent Ductus Arteriosus in Preterm Infants-The PDA RCT.
Tim Hundscheid1, Willem P de Boode1
1Radboud University Medical Center, Amalia Children's Hospital, Nijmegen, the Netherlands.
Expectant management and medication for patent ductus arteriosus in preterm infants showed similar outcomes. The PDA trial found no significant difference in major morbidities between the two approaches.
Area of Science:
- Neonatal Medicine
- Pediatric Cardiology
- Clinical Trials
Background:
- Patent ductus arteriosus (PDA) is common in preterm infants.
- Treatment decisions involve expectant management versus medication.
- Evidence comparing these strategies is limited.
Purpose of the Study:
- To compare expectant management with medication for PDA in preterm infants.
- To evaluate the impact on major morbidities.
Main Methods:
- Randomized clinical trial (PDA trial).
- Inclusion of preterm infants with PDA.
- Comparison of expectant management versus pharmacological treatment.
Main Results:
- No significant difference in the composite outcome of death or major morbidities.
- Similar rates of surgical intervention between groups.
- Exploration of secondary outcomes.
Conclusions:
- Expectant management and medication are comparable for PDA in preterm infants.
- Clinical decision-making can be individualized.
- Further research on long-term effects is warranted.
Related Concept Videos
Rheumatic Heart Disease III: Medical Management
Aortic Regurgitation III: Medical Management
Mitral Stenosis III: Medical Management
Mitral Regurgitation III: Medical Management
Mitral Valve Prolapse III: Nursing Management
Cardiopulmonary Resuscitation II: ACLS Airway Management

